Summary:
A MULTICENTER, RANDOMIZED, DOUBLE BLIND, ACTIVE CONTROLLED, PARALLEL GROUP, PHASE 3 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ADD ON THERAPY WITH SAZAGLIPTIN AND DAPAGLIFLOZIN ADDED TO METFORMIN COMPARED TO ADD ON THERAPY WITH SAZAGLIPTIN IN COMP\BINATION WITH METFORMIN OR DAPAGLIFLOZIN IN COMBINATION WITH METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON METFORMIN ALONE.
Qualified Participants Must:
• have type 2 DM, on Metformin 1500mg at least, and 18 years old and above
Qualified Participants May Receive:
$50 FOR EACH COMPLETED VISIT FOR A TOTAL OF 7 VISITS, OFFICE VISITS, MEAL TOLERANCE TEST, LABS, ECG, PHYSICAL, STUDY MEDICATION, GLUCOSE TESTING MACHINE AND TEST STRIPS AT NO CHARGE